190 related articles for article (PubMed ID: 31424273)
21. Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.
Rogowski W; Wachuła E; Lewczuk A; Kolasińska-Ćwikła A; Iżycka-Świeszewska E; Sulżyc-Bielicka V; Ćwikła JB
Future Oncol; 2017 May; 13(12):1069-1079. PubMed ID: 28095720
[TBL] [Abstract][Full Text] [Related]
22. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
Ryan P; Phan AT; Adelman DT; Iwasaki M
Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
[TBL] [Abstract][Full Text] [Related]
23. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
24. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
Pasricha G; Padhi P; Daboul N; Monga DK
Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
[TBL] [Abstract][Full Text] [Related]
25. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.
Keck KJ; Maxwell JE; Menda Y; Bellizzi A; Dillon J; O'Dorisio TM; Howe JR
Surgery; 2017 Jan; 161(1):272-279. PubMed ID: 27863780
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine Gastroenteropancreatic Tumors: Where Are We?
Ulla Rocha JL; Salgado A; Sardina Ferreiro R; Fernandez Catalina P; Gallardo E
Surg Laparosc Endosc Percutan Tech; 2017 Feb; 27(1):36-41. PubMed ID: 27977507
[TBL] [Abstract][Full Text] [Related]
27. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
28. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
29. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
30. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
[TBL] [Abstract][Full Text] [Related]
31. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
32. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
33. Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).
Manfredi S; Walter T; Baudin E; Coriat R; Ruszniewski P; Lecomte T; Laurenty AP; Goichot B; Rohmer V; Roquin G; Cojocarasu OZ; Lombard-Bohas C; Lepage C; Morcet J; Cadiot G
Endocrine; 2017 Sep; 57(3):504-511. PubMed ID: 28664309
[TBL] [Abstract][Full Text] [Related]
34. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
[TBL] [Abstract][Full Text] [Related]
35. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
Kalshetty A; Ramaswamy A; Ostwal V; Basu S
Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
[TBL] [Abstract][Full Text] [Related]
36. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
37. The importance of clinical information in patients with gastroenteropancreatic neuroendocrine tumor.
Kudo A; Akashi T; Kumagai J; Ban D; Inokuchi M; Kojima K; Kawano T; Tanaka S; Arii S
Hepatogastroenterology; 2012; 59(120):2450-3. PubMed ID: 22584507
[TBL] [Abstract][Full Text] [Related]
38. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
[TBL] [Abstract][Full Text] [Related]
39. Plasma chromogranin A levels predict survival and tumor response in patients with advanced gastroenteropancreatic neuroendocrine tumors.
Chou WC; Chen JS; Hung YS; Hsu JT; Chen TC; Sun CF; Lu CH; Hwang TL
Anticancer Res; 2014 Oct; 34(10):5661-9. PubMed ID: 25275071
[TBL] [Abstract][Full Text] [Related]
40. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
Cives M; Soares HP; Strosberg J
Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
